Pacific Biosciences of California (PACB)

Pacific Biosciences of California stock price today, ATLAS forecast and fair value

Healthcare · Medical Devices · NASDAQ

$2.45▲ +8.89%

Prices as of Oct 27, 2026 · USD

ATLAS fair value

ATLAS has no fair value for this stock today.

Chance of rising in 1 month

43%

that it ends higher than today in 21 sessions

0%coin flip 50%100%

This is just the summary. See everything on Pacific Biosciences of California in ATLAS

ATLAS's own quantitative analysis, all in one place.

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.

See everything included

Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

On Pacific Biosciences of California

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.

And for you

ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

Get started →

Plans from €3.99 a month.

ATLAS's model gives Pacific Biosciences of California a 43% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.

In half of the simulated outcomes the price ends between $1.92 and $2.84; in 9 out of 10, between $1.36 and $4.01. Estimated annual volatility is 120%.

Price, last 12 months (weekly close)

Key numbers

Market cap: $790M
52-week high: $3.44
52-week low: $1.07
Revenue (12 months): $159M
Revenue growth (YoY): +3.9%
Gross margin: 28.6%
Operating margin: -348.5%
Net margin: -341.5%
Free cash flow (12 months): $292M
Beta: 2.31

What this means

ATLAS does not publish a fair value for PACB right now, but it does show its odds of rising: somewhat worse than a coin flip.

Over the last 52 weeks PACB has traded between $1.07 and $3.44. Today it is 28.8% below that high and 129% above its low.

On the business: revenue grew 3.9% year over year; net margin is 341.5%.

Its beta is 2.31: it tends to move more than the market, both up and down.

About the company

Pacific Biosciences of California, Inc. Common Stock represents Pacific Biosciences of California, Inc., a life science technology company focused on designing, developing, and manufacturing advanced DNA sequencing solutions.

Want to see everything about Pacific Biosciences of California?

Get started →

Plans from €3.99 a month.

Comparable companies

Other companies in the same line of business:

Frequently asked questions

What does Pacific Biosciences of California do?

What is the chance PACB goes up next month?

43%: somewhat worse than a coin flip. In half of the simulated outcomes, PACB ends the month between $1.92 and $2.84.

How big is Pacific Biosciences of California and what is its P/E ratio?

Pacific Biosciences of California's market capitalization is $790M. We do not show a P/E because it has no positive earnings to base one on.

How volatile is PACB?

ATLAS estimates annual volatility at 120%. In a typical month, half of the outcomes end between $1.92 and $2.84.

Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer